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Abstract The objective of this study was to prospectively
assess the prevalence, predictors and prognostic signifi-
cance of microalbuminuria in a large cohort of consecutive
acute cardiac patients, admitted to an intensive cardiac care
unit from 1 January 2008 to 30 June 2009. In 815 acute
cardiac patients, microalbuminuria is detectable in 39.3%.
Microalbuminuria shows a significant negative correlation
with left ventricular ejection fraction (Spearman’s q =
-0.228; p \ 0.001), while it is positively correlated with
C-reactive protein (Spearman’s q = 0.239; p \ 0.001),
NT-pro-BNP (Spearman’s q = 0.306; p \ 0.001) and
glycemia (Spearman’s q = 0.191; p \ 0.001). Microalbu-
minuria is an independent predictor for in-hospital mortality
(1 lg/min step) (OR 1.015; 95% CI 1.008–1.023; p \
0.001). In the acute phase of cardiac patients, microalbu-
minuria is a common finding, and it represents an inde-
pendent predictor for early mortality. It is strictly linked to
the inflammatory activation (as indicated by C-reactive
protein) and to acute glucose values, thus suggesting that it
may be part of the acute response to stress.
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Introduction
Microalbuminuria is a known marker of vascular perme-
ability and endothelial dysfunction, and has been found to
be predictive of outcome in a wide variety of chronic and
acute conditions such as neoplastic disease [1, 2], surgery
[3], acute pancreatitis [4] and trauma [5].
In acute setting, microalbuminuria has been shown to be
a useful tool to predict illness severity and outcome in
critically ill adult patients admitted to an intensive care unit
(ICU) [6–8], but in these studies acute cardiac patients are
scarcely or not represented. Gopal et al. [6] report that
microalbuminuria predicts ICU mortality and inotrope
requirement, as well as or better than APACHE II and
SOFA scores in a mixed population (including about 10%
cardiac surgery patients). Similar results are reported by
Abid et al. [7] in a small subset of 40 medical patients
(three patients with cardiorespiratory arrest), and by
Thorevska et al. [9] in 104 critically ill patients (sepsis was
present in the 43.3% of all population).
The aim of the present investigation was therefore to
prospectively assess the prevalence, predictors and prog-
nostic significance of microalbuminuria in a large cohort of
consecutive acute cardiac patients, admitted to our inten-
sive cardiac care unit (ICCU).
Methods
We prospectively enrolled all 888 patients admitted to our
ICCU from 1 January 2008 to 30 June 2009. Exclusion
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criteria were as follows: pre-existing chronic renal failure
(60 patients), no urine output on the first day of admission,
on renal replacement therapy, or overtly bloody urine
(13 patients) [9]. Our study population was 815 patients.
Microalbuminuria was measured on the first day of
admission (in the overnight urine collection), and was
defined as ranging from 20 to 200 lg/min [10]. On ICCU
admission, after PCI, in a fasting blood sample the fol-
lowing parameters were measured: glucose (g/l), troponin I
(Tn I, ng/ml), uric acid (mg/dl) [11], NT-pro brain natri-
uretic peptide (NT-BNP) (pg/ml) [12], leukocytes count
(9103/ll), fibrinogen (mg/dl), erythrocyte sedimentation
rate (ESR), lactate, C-reactive protein (C-RP, mg/dl).
Creatinine (mg/dl) was also measured in order to calculate
glomerular filtration rate (ml/min/1.73 m2) [13]. Glucose
values were measured three times a day and peak glucose
was considered. In patients with STEMI and UA/NSTEMI
Tn I was measured three times a day and peak Tn I was
reported [11, 12].
Transthoracic 2-dimensional echocardiography was
performed on ICCU admission in order to measure left
ventricular ejection fraction (LVEF).
In-ICCU mortality was the end point of outcome in our
study.
Statistical analysis
Data were processed by means of SPSS 13.0 statistical
package (SPSS Inc., Chicago, IL, USA). A two-tailed
p value\0.05 was considered statistically significant. Data
are reported as frequencies (percentages) and medians
[95% Confidence Interval (CI)] and analyzed by means of
v2 (or Fisher’s exact text, when appropriate) and Mann–
Whitney U test. By means of Spearman’s rho the correla-
tions between the presence of microalbuminuria, LVEF,
C-reactive protein, admission glycemia and NT-pro BNP
were assessed. A backward stepwise logistic regression
analysis was conducted in order to identify the variables
correlated to microalbuminuria and in-ICCU death. In the
logistic models, candidate variables were chosen as those
that were significantly different at univariable analysis, or
were clinically relevant. Backward procedure (probability
for entry 0.05; probability for removal 0.10) was repeated
until all variables in the model reached statistical signifi-
cance. For each model, calibration was assessed by means
of a Hosmer–Lemeshow goodness of fit test; pseudo R2
were also assessed. Receiver operating characteristic
(ROC) curves were constructed for microalbuminuria and
in-ICCU death.
Results
Our series comprises the following subgroups according to
admission diagnosis, as follows:
1. ST elevation myocardial infarction [14]: in our hospi-
tal, in Florence, the reperfusion strategy of STEMI
patients is represented by primary PCI [12]. The
patients are first evaluated by the Medical Emergency
System in the pre-hospital setting, and then directly
admitted to the catheterization laboratory or trans-
ferred to it after a rapid stabilization in the emergency
department (ED). After primary PCI, they are admitted
to our ICCU.
Table 1 Clinical
Characteristics of the 815
patients included into the study
IR interquartile range, STEMI
ST elevation myocardial
infarction, UA/NSTEMI
unstable angina/Non ST
elevation myocardial infarction,
LOS length of stay, ICCU
intensive cardiac care unit
Median (IR) or
frequency (%)
Age [median (IR), years] 72 (62–79)
Gender [Males/Females, frequency (%)] 549/266 (67.4/32.6)
Comorbidities
Diabetes mellitus [frequency (%)] 200 (24.5)
Hypertension [frequency (%)] 524 (64.3)
Diagnoses
STEMI [frequency (%)] 252 (30.9)
UA/NSTEMI [frequency (%)] 330 (40.5)
Acute heart failure [frequency (%)] 81 (9.9)
Arrhythmias [frequency (%)] 36 (4.4)
Other [frequency (%)] 116 (14.2)
LOS [median (IR), h] 72 (48–96)
In-ICCU mortality [frequency (%)] 33 (4.0)
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2. Unstable angina/non-ST elevation myocardial infarc-
tion [15]
3. Acute heart failure (AHF) [16]
4. Dyarhythmias
5. Other (i.e. stable angina, pulmonary embolism)
Table 1 depicts the clinical characteristics of the 815
patients included in the study. Men are more prevalent
(67.4%), and hypertension is present in more than half of
the patients (64.3%). Acute coronary syndrome (that is
STEMI and UA/NSTEMI) is the most frequent admission
diagnosis accounting for 71.4%. In-ICCU mortality rate
was 4% (33/815).
Among patients with estimated glomuerular filtration rate
(eGFR) C60 ml/min/1.73 m2 (who accounted for 84.4%),
microalbuminuria is detectable in the 35%, while in patients
with eGFR\60 ml/min/1.73 m2 it is found in 62.4%.
Table 2 depicts the comparison between the patients
with microalbuminuria and those without. In our series,
microalbuminuria is detectable in 39.3% (294/815
patients). Patients with microalbuminuria are older
(p \ 0.001), more hypertensive (p \ 0.001) and diabetic
(0.02). They show lower values of LVEF (p \ 0.001) and
eGFR (p \ 0.001) and higher values of NT-pro BNP
(p \ 0.001), Tn I (p = 0.005), uric acid (p \ 0.001),
glycemia (p \ 0.001) and lactate (p \ 0.001). A higher
inflammatory activation is observed in patients with
microalbuminuria, as inferred by the higher values of
C-reactive protein (p \ 0.001), leukocytes (p \ 0.001),
fibrinogen (p \ 0.001). Length of stay is higher in patients
with microalbuminuria (p \ 0.001), as well as in-ICCU
mortality rate (p \ 0.001).
Microalbuminuria shows a significant negative correla-
tion with LVEF (Spearman’s q = -0.228; p \ 0.001),
while it is positively correlated with C-reactive protein
(Spearman’s q = 0.239; p \ 0.001), NT-pro-BNP (Spear-
man’s q = 0.306; p \ 0.001) and glycemia (Spearman’s
q = 0.191; p \ 0.001).
The following variables are independently associated
with the development of microalbuminuria (when adjusted
for age, hypertension, diabetes, eGFR, C-RP and EF): NT-
pro BNP (100 pg/ml step: OR 1.004; 95% CI 1.002–1.007;
p = 0.002); glycemia (1 g/dl step: OR 1.686; 95% CI
1.201 to 2.366; p = 0.003). Nagelkerke R2 0.16; Hosmer–
Lemeshow goodness of fit 6.329, p = 0.610.
At backward regression analysis, the following variables
are independent predictors for in-ICCU mortality: Admis-
sion eGFR (1 ml/min/1.73m2 step) (OR 0.973; 95% CI
0.959–0.988; p \ 0.001); LVEF (1% step) (OR 0.944; 95%
CI 0.914–0.975; p \ 0.001); Microalbuminuria (1 lg/min
step) (OR 1.017; 95% CI 1.010–1.024; p \ 0.001). Nage-
lkerke R2 0.34; Hosmer–Lemeshow goodness of fit 11.626,
p = 0.169.
Based on the ROC curve for the entire population, the
optimum microalbuminuria threshold for in-ICCU death
Table 2 Comparison between patients with and without microalbuminuria
No microalbuminuria 469 (57.5%) Microalbuminuria 346 (42.5%) p value
Age (years) 70 (59–78) 74 (64–82) \0.001
Gender [males/females, frequency (%)] 322/147 (68.7/31.3) 227/119 (65.6/34.4) 0.365
BMI [median (IR), kg/m2] 26.0 (24.0–28.0) 25.8 (23.1–28.0) 0.150
Hypertension [frequency (%)] 277 (59.1) 247 (71.4) \0.001
Diabetes [frequency (%)] 101 (21.5) 99 (28.6) 0.021
EF [median (IR), %] 50.0 (42.0–55.0) 45.0 (35.0–55.0) \0.001
NT-pro BNP [median (IR), pg/ml] 879 (257–2469) 2767 (832–8302) \0.001
Tn I [median (IR), ng/ml] 4.25 (0.21–44.85) 7.81 (0.46–63.45) 0.005
C-Reactive protein [median (IR), mg/dl] 9.0 (8.0–21.5) 17.0 (9.0–57.8) \0.001
Leukocytes [median (IR), 91000/ll] 8.1 (6.5–10.3) 9.7 (7.3–12.9) \0.001
Uric Acid [median (IR), mg/dl] 5.6 (4.7–6.7) 6.0 (5.0–7.4) \0.001
Glycemia [median (IR), g/l] 1.08 (0.91–1.38) 1.24 (0.98–1.69) \0.001
Fibrinogen [median (IR), mg/dl] 426 (357–505) 466 (400–563) \0.001
Lactate [median (IR), mmol/l] 0.90 (0.70–1.50) 1.50 (0.90–2.70) \0.001
eGFR [median (IR), ml/min/1.73 m2] 90.2 (74.8–106.8) 72.5 (47.2–102.7) \0.001
LOS [median (IR), %] (h) 61 (44–96) 72 (48–120) \0.001
Dead patients [frequency (%)] 3 (0.6%) 30 (8.7%) \0.001
BMI body mass index, IR interquartile range, EF left ventricular ejection fraction, NT-pro BNP N terminal pro Brain Natriuretic Peptide, Tn I
troponin I, eGFR estimated Glomuerular Filtration Rate, LOS length of stay
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should be 20 lg/min. This threshold would have yielded a
sensitivity of 91% (95% CI 76–98%) and a specificity of
60% (05% CI 56–63%). The positive predictive value is
8.7%, while the negative predictive value is 99.4%. The
corresponding RR for microalbuminuria[20 mg/dl is 13.6
(95% CI 4.5–41.7; p \ 0.001).
Discussion
The main finding of the present investigation is that in a
large cohort of consecutive acute cardiac patients, micro-
albuminuria on admission shows a high prevalence (being
detectable in the 39.3%), and it is an independent predictor
of in-ICCU mortality.
Microalbuminuria is recognized as a strong and inde-
pendent indicator of increased cardiovascular risk among
subjects with and without diabetes [17], its presence sub-
stantially increases the cardiovascular risk, and it is an
independent predictor of ischemic heart disease in a pop-
ulation-based cohort [18]. In chronic heart failure, elevated
albumin excretion is a powerful prognostic marker for all-
cause mortality, independent of diabetes, hypertension, or
renal function [19].
Our series includes mainly patients with acute coronary
syndromes who undergo mechanical revascularization
(accounting for 71.4% of the entire population), but
available evidence of the prognostic significance of mi-
croalbuminuria in these patients is so far controversial. In
patients with acute myocardial infarction (AMI) [20–22]
microalbuminuria has been reported to occur early, yield-
ing prognostic information about in-hospital mortality
additional to that provided by clinical or echocardiographic
evaluation of left ventricular function. In non-diabetic
patients with AMI [23], microalbuminuria has been shown
to be a predictor not only for mortality but even for mor-
bidity. In hypertensive patients with AMI [24], the com-
bination between microalbuminuria and hypertension is
associated with a higher risk of in-hospital mortality,
independent of other possible confounders (such as heart
failure). Previous investigations have been performed in
heterogeneous populations of patients with hypertension
and myocardial infarction, diabetic and non-diabetic, sub-
mitted either to thrombolysis or to mechanical revascu-
larization or not revascularized. Conversely, in our paper
[25], in the early phase of 257 STEMI hypertensive
patients without previously known diabetes all submitted to
mechanical revascularization, microalbuminuria, though a
common finding, did not yield prognostic information
about in-hospital mortality or complications.
In the present investigation, microalbuminuria shows a
strong independent prognostic role for early mortality,
independent of the admission diagnosis. This can be
probably related to the fact that microalbuminuria is strictly
linked to the inflammatory activation (as inferred by C-RP)
and glucose values, as a part of the acute stress response.
C-RP is a well known prognostic marker in cardiovascular
diseases, both in chronic and acute cardiac conditions [26–
29]. In a previous paper [25] performed in hypertensive
non-diabetic STEMI patients, microalbuminuria was
associated with acute glucose dysmetabolism (as inferred
by hyperglycemia and the prevalence of insulin-resistance),
thus suggesting that it can be considered as the part of the
acute metabolic response to stress.
In our series, microalbuminuria correlates with NT-pro
BNP values, which is known as a strong predictor for
cardiovascular mortality [30]. Our findings are in agree-
ment with recent investigations performed in humans [31]
and in animal models [32]. In Japanese hypertensive
patients, a concomitant reduction in BNP and microalbu-
minuria is observed after therapy [33], while in hyperten-
sive rats, microalbuminuria is significantly correlated with
reductions in cardiac mass and hypertrophy markers (such
as BNP), thus suggesting a potential link between micro-
albuminuria and BNP. In the acute phase of STEMI [10],
NT-pro BNP is related to the extension of myocardial
injury (as inferred by peak Tn I), and to inflammatory
activation (as indicated by C-RP). It is an independent
predictor for early mortality.
The main limitation of the present study is that it comprises
unselected patients admitted to our ICCU because of varying
diagnoses (from acute coronary syndrome to acute pulmonary
embolism). On the other hand, our population including
consecutive acute cardiac patients, reflects the ‘‘contempo-
rary clinical practice’’ in an ICCU of a tertiary center.
In conclusion, in the acute phase of cardiac patients,
microalbuminuria is a common finding and it represents an
independent predictor for early mortality. It is strictly
linked to the inflammatory activation (as indicated be
C-RP) and to acute glucose values, thus suggesting that it is
the part of the acute response to stress.
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